Savills unveils top spots for life sciences in Europe
Paris and established locations in the Netherlands (Randstad) and Switzerland (Lausanne/Geneva and Zurich) are the top spots for life science occupiers in Europe.
This is based on analysis conducted by the international real estate advisor encompassing around 60 metrics across talent, innovation, industrial output, investment, occupier activity, and social infrastructure.
The top locations also include Berlin and Munich in Germany; Basel in Switzerland; Copenhagen in Denmark and the Frankfurt/Karlsruhe region in Germany.
Taking a closer look at Germany and Denmark, Savills has witnessed some specialist operators emerging in the former and expects to see an increase in dedicated management solutions. Another growing market that has attracted great investor attention is Copenhagen. The Danish capital has a strong concentration of life science companies and is home to 75% of all such firm based in the country.
George Coleman, associate director, European Capital Markets at Savills, says: “As the life sciences sector continues to evolve in Europe understanding the fundamental attractiveness of locations is paramount to ensure the long-term return on investment.”
“Our ranking highlights emerging locations in which the sector is growing rapidly, and investors are following a development-led strategy due to the lack of purpose-built stock, whereas in the more established locations there are some opportunities to reposition existing repriced buildings, subject to technical capability.”
Sarah Thorley, associate director, Strategic Advisory EMEA at Savills, says: “Given the current economic headwinds, less established life science markets are facing challenges in respect of the funding environment and much of the capital into the sector is being concentrated in more established locations. Investors are shaping their strategies around these top markets, that can demonstrate sustained demand.
“For example, Paris is home to over 1,000 life science companies across various scientific subsectors with around 70 global pharmaceutical companies who have more than 10,000 employees across the world. Paris is attracting considerable attention from investors and developers who are bringing purpose built stock to the market.”
To read the report, please visit: https://www.savills.co.uk/research_articles/229130/355123-0